Genmab — Januar 2026
-
Marketwire Flere tilpasninger i sigte. "Genmab skal have forretning set efter i sømmene og mangler stadig at gøre nogle tilpasninger i forbindelse med købet af det hollandske biotekselskab Merus for godt 50 mia. kr. i efteråret 2025." + Merus 8 partnerskaber skal gennemgås "Vi vil være meget omhyggelige, men også beslutsomme, ligesom vi var med Acasunlimab, siger Jan van de Winkel."
-
De står bare på en aktiesparekonto , hvor der kun er de aktier til mine to børnebørn. Min datter og svigersøn, samt min kone ved alt om det, hvis jeg dør først. Du har ret det er svært at oprette når barnet er nogle få måneder. Jeg var i banken o.s.v men det var ikke bare lige til.
-
Du kan faktisk oprette en aldersopsparing Til børn, Det har jeg selv gjort til min datter og det er nemt og billigt skattemæssigt. Ikke så sexet men super fornuftig. Og perfekt til en aggressiv strategi. Det kan lære dem at se maling tørre.
-
Gevinsthjemtagning i 2242 . Ligger med disse i Saxodepotet https://nbg1.your-objectstorage.com/proinvestor-dev/forum/boards/130704_Skaermbillede_2026_01_15_081238.jpg
-
-
Genmab får hævet kursmål til 2300 kr. fra 2000 kr. hos Jyske Bank https://proinvestor.com/investornyt/1403296/genmab-far-haevet-kursmal-til-2300-kr-fra-2000-kr-hos-jyske-bank
-
TECVAYLI
monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide https://www.jnj.com/media-center/press-releases/tecvayli-monotherapy-demonstrates-superior-progression-free-and-overall-survival-versus-standard-of-care-as-early-as-first-relapse-in-patients-with-multiple-myeloma-predominantly-refractory-to-anti-cd38-therapy-and-lenalido -
Why Does Rina-S Target Folate Receptor Alpha in Endometrial Cancer? https://www.oncnursingnews.com/view/why-does-rina-s-target-folate-receptor-alpha-in-endometrial-cancer-
-
Regnskabets time nærmer sig for C25-selskaberne, og Helge Larsen er meget spændt på, hvordan de selv guider for 2026 - et år, der tegner til at blive meget udfordrende. Han dykker ned i fremtidsudsigterne hos nogle af ProInvestors mest omtalte selskaber. Bla. Maersk, Novo, Genmab, Pandora og GN Store Nord. Kort video: https://proinvestor.com/boards/130714/
-
[Latest] Global T-Cell Engagers Market Size/Share Worth USD 18.8 Billion by 2034 at a 21.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global T-Cell Engagers Market size & share revenue was valued at approximately USD 2.4 Billion in 2024 and is expected to reach USD 2.5 Billion in 2025 and is expected to reach around USD 18.8 Billion by 2034, at a CAGR of 21.2% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Amgen, Genmab, Roche/Genentech, Ma
Yahoo Finance (finance.yahoo.com)
-
For the Dutch : Dr. Marcel Nijland over epcoritamab met R2 bij R/R folliculair lymfoom https://www.mednet.nl/congres-nieuws/dr-marcel-nijland-over-epcoritamab-met-r2-bij-r-r-folliculair-lymfoom/
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind